DCTY Biotech Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $26.3M

DCTY Biotech General Information

Description

Researcher of tumor molecular-targeted cellular immunotherapy drugs designed for oncology treatment. The company focuses on R&D of tumor molecular targeted specific cellular immunotherapy drugs and technologies as well as operating a modern molecular biology, cell biology laboratory and detection platform, enabling the development and promotion of tumor molecular targeting specific cellular immunotherapy technology.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • Building 4, No. 86, Shuangying West Road
  • Nanshao, Changping District
  • Beijing, 102200
  • China
+86 010
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Building 4, No. 86, Shuangying West Road
  • Nanshao, Changping District
  • Beijing, 102200
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DCTY Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 09-Nov-2024 $26.3M Completed Generating Revenue
2. Later Stage VC 14-Jan-2022 Completed Generating Revenue
1. Later Stage VC 05-Jul-2021 Completed Generating Revenue
To view DCTY Biotech’s complete valuation and funding history, request access »

DCTY Biotech Patents

DCTY Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025140683-A1 Engineered immune cell expressing chemokine 10 and interleukin 15 Inactive 29-Dec-2023
AU-2024268481-A1 Tcr molecule targeting kras g12v mutation, cell, and uses thereof Pending 06-May-2023
EP-4660206-A1 Tcr molecule targeting kras g12v mutation, cell, and uses thereof Pending 06-May-2023
US-20260250388-A1 Tcr molecule targeting kras g12v mutation, cell, and uses thereof Pending 06-May-2023
WO-2024230630-A1 Tcr molecule targeting kras g12v mutation, cell, and uses thereof Inactive 06-May-2023 C07K14/7051
To view DCTY Biotech’s complete patent history, request access »

DCTY Biotech FAQs

  • When was DCTY Biotech founded?

    DCTY Biotech was founded in 2014.

  • Where is DCTY Biotech headquartered?

    DCTY Biotech is headquartered in Beijing, China.

  • What industry is DCTY Biotech in?

    DCTY Biotech’s primary industry is Biotechnology.

  • Is DCTY Biotech a private or public company?

    DCTY Biotech is a Private company.

  • What is the current valuation of DCTY Biotech?

    The current valuation of DCTY Biotech is .

  • What is DCTY Biotech’s current revenue?

    The current revenue for DCTY Biotech is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process